Aart Jan van der Lely
Gründer bei Millendo Therapeutics SAS
Ursprung des Netzwerks ersten Grades von Aart Jan van der Lely
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
International Society of Endocrinology
 International Society of Endocrinology Miscellaneous Commercial ServicesCommercial Services International Society of Endocrinology specializes in worldwide advancement of education, science and patient care in endocrinology. It engages in the guide and providing information in endocrinology to the public. The company was founded in 1960 and is headquartered in Bradley Stoke, the United Kingdom.
9
| Non-Profit Organization | Miscellaneous Commercial Services | 9 |
Millendo Therapeutics SAS
 Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France.
7
| Subsidiary | Medical Specialties | 7 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Aart Jan van der Lely
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
UCB Pharma GmbH
 UCB Pharma GmbH Pharmaceuticals: MajorHealth Technology UCB Pharma GmbH manufactures and develops drugs. It manufactures prescription and non-prescription drugs. With its partners, the company engages in biopharmaceutical research and development. Apart from providing medication, the company provides support to the patients. The company was founded in 1928 and is headquartered in Monheim, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| THERATECHNOLOGIES INC. | Pharmaceuticals: Major | Founder Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| SANOFI | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| TIGENIX NV | Medical Specialties | Director/Board Member | |
| KIORA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Ubiquisys Ltd.
 Ubiquisys Ltd. Computer CommunicationsElectronic Technology Ubiquisys Ltd. provides communication services. The company was founded on October 1, 2004 and is headquartered in Cardiff, the United Kingdom. | Computer Communications | Corporate Officer/Principal | |
Millendo Therapeutics US, Inc.
 Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Pharmaceuticals: Major | Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Bath | College/University | Doctorate Degree | |
Sofimac Innovation SAS
 Sofimac Innovation SAS Investment ManagersFinance Sofimac Innovation SAS is an independent, early-stage venture capital firm which was created in 1998 by Eric Harlé and Didier Moret. Headquartered in Paris, France, Sofimac Innovation manages venture capital funds which provide equity financing for start-ups and early-stage companies in the Information and Communication Technologies (Software, SaaS, Multimedia and Telecom) sector. | Investment Managers | Director/Board Member Private Equity Investor | |
Turenne Capital Partenaires SA
 Turenne Capital Partenaires SA Investment ManagersFinance Turenne Capital Partenaires SA (Turenne Capital) is a venture capital subsidiary of Turenne Associés SA founded in 1999 by Aymard de Lasteyrie. The firm is headquartered in Paris, France. | Investment Managers | Private Equity Investor | |
Ventech SA
 Ventech SA Investment ManagersFinance Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US. | Investment Managers | Private Equity Investor | |
| SCYNEXIS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| University of Montréal | College/University | Undergraduate Degree Doctorate Degree | |
| University of Paris Jussieu | College/University | Doctorate Degree | |
| École Centrale Paris | College/University | Undergraduate Degree | |
| PIERREL S.P.A. | Pharmaceuticals: Other | Corporate Officer/Principal | |
| Institut National Polytechnique de Toulouse | College/University | Doctorate Degree | |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium. | Biotechnology | Director/Board Member | |
| QIAGEN MARSEILLE | Miscellaneous Commercial Services | Director/Board Member | |
| The University of Algiers | College/University | Doctorate Degree | |
Eye Tech Care SA
 Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France. | Medical Specialties | Director/Board Member | |
| University of Turin | College/University | Chairman | |
Covagen AG
 Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Biotechnology | Director/Board Member | |
| Kabivitrum AB | Corporate Officer/Principal | ||
| Pfizer NV/SA | Corporate Officer/Principal | ||
EUSA Pharma SAS
 EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Biotechnology | Chief Executive Officer Chief Executive Officer | |
Jazz Pharmaceuticals UK Ltd.
 Jazz Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Ipsen NV
 Ipsen NV Pharmaceuticals: MajorHealth Technology Part of Ipsen SA, Ipsen NV is a Belgian biopharmaceutical company that improves patients' lives through research and innovation in oncology, rare disease, and neuroscience. Founded in 1982, the company is based in Merelbeke, Belgium. Ipsen is a global mid-sized biopharmaceutical company that focuses on improving patients' lives through its research and innovation in the field of oncology, rare diseases, and neuroscience. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Themis Bioscience GmbH
 Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Director/Board Member | |
| Finbiomed SARL | Chief Executive Officer | ||
Amolyt Pharma SAS
 Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder Director/Board Member | |
Adienne SA
 Adienne SA Pharmaceuticals: OtherHealth Technology Adienne SA is a biopharmaceutical company engages in the provision of medical development. It focuses on orphan drugs for the treatment of various haematological and immunological diseases. The company was founded on Lugano, Switzerland. | Pharmaceuticals: Other | Director/Board Member | |
European Society of Endocrinology
 European Society of Endocrinology Miscellaneous Commercial ServicesCommercial Services The European Society of Endocrinology is an organization that aims to improve science, knowledge, and health in the field of endocrinology. The private company is based in Bristol, UK. The British company unites, support, and represent their community to drive better medical outcomes. The company was founded by Jens Sandahl Christiansen. Helen Gregson has been the CEO of the company since 2006. | Miscellaneous Commercial Services | President Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
ORPHELIA Pharma SAS
 ORPHELIA Pharma SAS Pharmaceuticals: MajorHealth Technology ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman | |
Jazz Pharmaceuticals II SASU
 Jazz Pharmaceuticals II SASU Pharmaceuticals: MajorHealth Technology Jazz Pharmaceuticals II SASU engages in the development of biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases. Its lead assets are pegcrisantaspase (Asparec), a PEGylated recombinant L-asparaginase from Erwinia chrysanthemi, and related intellectual property. The company was founded in 2008 and is headquartered in Ecully, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Opi Pharma | Chief Executive Officer | ||
Physio-Assist SAS
 Physio-Assist SAS Medical SpecialtiesHealth Technology Physio-Assist SAS develops an expertise in bronchial mucus analysis and clearance. The company was founded by Adrien Mithalal on September 17, 2012 and is headquartered in Aix en Provence, France. | Medical Specialties | Director/Board Member | |
Polyplus-transfection SA
 Polyplus-transfection SA BiotechnologyHealth Technology Polyplus-transfection SA develops and sells solutions for the delivery of nucleic acids in research, bio production, and therapeutics. Its products are transfection reagents and trademarks, mainly for gene and cell therapies. The company was founded by Jean-Paul Behr, Anne-Lise Monjanel, Joelle Bloch, and Patrick Metz in January 2001 and is headquartered in Illkirch-Graffenstaden, France. | Biotechnology | Director/Board Member |
Statistik
International
| Frankreich | 23 |
| Vereinigtes Königreich | 7 |
| Vereinigte Staaten | 5 |
| Belgien | 5 |
| Kanada | 4 |
Sektoral
| Health Technology | 30 |
| Consumer Services | 9 |
| Finance | 5 |
| Commercial Services | 5 |
| Electronic Technology | 2 |
Operativ
| Director/Board Member | 78 |
| Corporate Officer/Principal | 20 |
| Chief Executive Officer | 13 |
| Founder | 10 |
| Chairman | 8 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Aart Jan van der Lely
- Unternehmensverbindungen
